Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF, Agulnik J, Akerborg O, Chouaid C, De Geer A, Finnern HW, Herder GJ, Lungershausen J, Mitchell PL, Vansteenkiste J, Ziske C, Goker E. Lester JF, et al. Among authors: vansteenkiste j. Lung Cancer. 2013 Oct;82(1):128-35. doi: 10.1016/j.lungcan.2013.06.023. Epub 2013 Jul 31. Lung Cancer. 2013. PMID: 23910909
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H. Thatcher N, et al. Among authors: vansteenkiste jf. Br J Cancer. 1999 May;80(3-4):396-402. doi: 10.1038/sj.bjc.6690369. Br J Cancer. 1999. PMID: 10408844 Free PMC article. Clinical Trial.
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, van Zandwijk N, van Tinteren H, Smit EF. Hoekstra CJ, et al. Among authors: vansteenkiste j. Lung Cancer. 2003 Feb;39(2):151-7. doi: 10.1016/s0169-5002(02)00446-4. Lung Cancer. 2003. PMID: 12581567
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquée L, Delobbe A, Deschepper K, Van Kerckhoven W, Vandeurzen K, Deman R, D'Odemont JP, Siemons L, Van den Brande P, Dams N; Leuven Lung Cancer Group. Vansteenkiste J, et al. Lung Cancer. 2003 May;40(2):191-9. doi: 10.1016/s0169-5002(02)00515-9. Lung Cancer. 2003. PMID: 12711121 Review.
Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer.
Postmus PE, Rocmans P, Asamura H, Ball D, Belderbos J, Cappello M, Jassem J, Novello S, Pass H, Passlick B, Pirker R, Ready N, Sause W, Scagliotti G, Vansteenkiste J, Westeel V, van Zandwijk N. Postmus PE, et al. Among authors: vansteenkiste j. Lung Cancer. 2003 Dec;42 Suppl 1:S3-6. doi: 10.1016/s0169-5002(03)00296-4. Lung Cancer. 2003. PMID: 14708514 Review. No abstract available.
363 results